Mining Twitter Hashtags to Find Unknown Drug Issues
A team of scientists at the University of Vermont has invented a new technique for discovering potentially dangerous drug interactions and unknown side-effects using Twitter hashtags.
A team of scientists at the University of Vermont has invented a new technique for discovering potentially dangerous drug interactions and unknown side-effects using Twitter hashtags.
Previous studies have shown that Twitter can be mined for bad drug interactions, but the Vermont team advances this idea by focusing on the distinctive information contained in hashtags-like “#overprescribed,” “#kidneystoneprobs,” and “#skinswelling”-to find new associations. The overall goal of the project, supported by the National Science Foundation, was to discover is to discover any relationship between two drugs that is not known.
Using their new algorithm, the team has created a website that will allow an investigator to explore the connections between search terms (say "albuterol"), existing scientific studies indexed in PubMed-and Twitter hashtags associated with the terms and studies.
A report on how the algorithm works, and its preliminary discoveries, was published online, June 8, in the Journal of Biomedical Informatics.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
